CDK4/6i have brought significant improvements in the treatment of metastatic and early high-risk BC, but it is now clear that some patients do not benefit from these agents, showing de novo resistance, and even the responders eventually recur, experiencing acquired resistance. The gene discussed is CDK4; the disease is breast cancer.